Technical Analysis for KALV - KalVista Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 8.96 | -0.99% | -0.09 |
Earnings due: Dec 5
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Buy Signal | Bullish | -0.99% | |
| NR7 | Range Contraction | -0.99% | |
| Lower Bollinger Band Walk | Weakness | -0.99% | |
| Inside Day | Range Contraction | -0.99% |
| Alert | Time |
|---|---|
| Possible NR7 | about 18 hours ago |
| 60 Minute Opening Range Breakdown | about 20 hours ago |
| Up 2% | about 20 hours ago |
| Fell Below Previous Day's Low | about 21 hours ago |
| Down 1% | about 21 hours ago |
Get a Trading Assistant
- Earnings date: 12/05/2024
KalVista Pharmaceuticals, Inc. Description
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Disease Organ Systems Eye Enzymes Stage Pharmaceutical Macular Edema Diabetic Macular Edema Angioedema Hereditary Angioedema Kallikrein Complement Deficiency C1 Inhibitor Plasma Kallikrein Protease Inhibitor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.88 |
| 52 Week Low | 7.39 |
| Average Volume | 425,429 |
| 200-Day Moving Average | 12.18 |
| 50-Day Moving Average | 11.06 |
| 20-Day Moving Average | 10.77 |
| 10-Day Moving Average | 10.14 |
| Average True Range | 0.67 |
| RSI (14) | 30.07 |
| ADX | 19.22 |
| +DI | 18.25 |
| -DI | 29.96 |
| Chandelier Exit (Long, 3 ATRs) | 10.83 |
| Chandelier Exit (Short, 3 ATRs) | 10.77 |
| Upper Bollinger Bands | 12.71 |
| Lower Bollinger Band | 8.83 |
| Percent B (%b) | 0.03 |
| BandWidth | 36.11 |
| MACD Line | -0.62 |
| MACD Signal Line | -0.38 |
| MACD Histogram | -0.2423 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.72 | ||||
| Resistance 3 (R3) | 9.78 | 9.59 | 9.59 | ||
| Resistance 2 (R2) | 9.59 | 9.40 | 9.56 | 9.55 | |
| Resistance 1 (R1) | 9.28 | 9.28 | 9.18 | 9.21 | 9.51 |
| Pivot Point | 9.09 | 9.09 | 9.04 | 9.05 | 9.09 |
| Support 1 (S1) | 8.77 | 8.89 | 8.68 | 8.71 | 8.41 |
| Support 2 (S2) | 8.58 | 8.77 | 8.55 | 8.37 | |
| Support 3 (S3) | 8.27 | 8.58 | 8.33 | ||
| Support 4 (S4) | 8.20 |
